Peripheral sympathetic nerve dysfunction in adolescent japanese girls following immunization with the human papillomavirus vaccine

Internal Medicine

Volumn 54, Issue 15, 2015, Pages 1953-

  Hanley, Sharon J B ^a   Pollock, Kevin G J ^b   Cuschieri, Kate ^c  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Adverse event following immunization; HPV vaccine; Japan; Neurological symptoms

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; DRUG INDUCED DISEASE; FEMALE; HUMAN; IMMUNIZATION; JAPAN; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PAPILLOMAVIRUS INFECTION; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; VACCINATION REACTION; ADRENERGIC SYSTEM; ADVERSE EFFECTS; AUTONOMIC NEUROPATHY; CHEMICALLY INDUCED; PAPILLOMAVIRUS INFECTIONS; PATHOPHYSIOLOGY;

AUTONOMIC NERVOUS SYSTEM DISEASES; FEMALE; HUMANS; IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SYMPATHETIC NERVOUS SYSTEM;

EID: 84938500405     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.4479     Document Type: Article

References (5)

1. Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 53: 2185-2200, 2014.
2. WHO, Causality Assessment of an Adverse Event Following Immunization (AEFI) [Internet]. [cited 2014 Nov. 1]. Available from: http://www.who.int/vaccine_safety/publications/gvs_aefi/en/
3. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 347: f5906, 2013.
4. MHRA Public Assessment Report, Cervarix HPV vaccine: update on UK safety experience at end of 4 years use in the HPV routine immunisation programme [Internet]. [cited 2014 Nov. 1]. Available from: http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-G-L/umanpapillomavirusHPVvaccine/CON023340
5. Pollock K, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 111: 1824-1830, 2014.